Management of the Uncommon Bladder Cancers: A Single-Center Experience over 10 Years.
Journal
Advances in urology
ISSN: 1687-6369
Titre abrégé: Adv Urol
Pays: Egypt
ID NLM: 101476240
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
05
2020
accepted:
22
07
2020
entrez:
21
10
2020
pubmed:
22
10
2020
medline:
22
10
2020
Statut:
epublish
Résumé
Under the name of uncommon bladder cancers are gathered rare histological entities which represent less than 5% of bladder tumors. There is not a clear and consensual therapeutic management for these entities. To review a single-institution 10-year experience with rare form of bladder cancers detailing the diagnosis, treatment, and patient outcome. We performed a retrospective review of 27 medical records of rare bladder cancer form treated at our center between February 2006 and February 2015. The clinicopathologic features are reported with emphasis on treatment and survival. Mean patient age was 65.5 ± 20 yr and 70% of patients were males. Smoking background was found in 16 cases, chronic bladder irritation factors were found in 12 cases, and past urinary tract infection was found in 11 cases. The main symptom was total hematuria (93%) causing an anemia in 16 cases. The two mean histological forms were epidermoid carcinoma (37%) and adenocarcinoma (22%). 26% of patients were found to have extended invasive tumors (T4) at diagnosis. Metastatic disease was confirmed in 8 cases. Our patients were managed by a wide range of therapeutic modalities as total cystectomy with bilateral lymph node dissection (63%), palliative chemotherapy (30%), or concomitant radiochemotherapy (7%). 55.6% of patients were alive one year after diagnosis. Epidermoid carcinoma has the best prognosis followed by leiomyosarcoma and sarcomatoid carcinoma. Neuroendocrine carcinoma has the worst outcome. The overall 5-year survival rate is 33.3%. The rarity and small size of these tumors justify the absence of clear and consensual therapeutic management. No role of total cystectomy concerning the conclusions could be drawn but elements suggest this may be the treatment of choice. The highly aggressive nature of those lesions justifies an aggressive and fast therapy when feasible which gives the best outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Under the name of uncommon bladder cancers are gathered rare histological entities which represent less than 5% of bladder tumors. There is not a clear and consensual therapeutic management for these entities.
PURPOSE
OBJECTIVE
To review a single-institution 10-year experience with rare form of bladder cancers detailing the diagnosis, treatment, and patient outcome.
MATERIALS AND METHODS
METHODS
We performed a retrospective review of 27 medical records of rare bladder cancer form treated at our center between February 2006 and February 2015. The clinicopathologic features are reported with emphasis on treatment and survival.
RESULTS
RESULTS
Mean patient age was 65.5 ± 20 yr and 70% of patients were males. Smoking background was found in 16 cases, chronic bladder irritation factors were found in 12 cases, and past urinary tract infection was found in 11 cases. The main symptom was total hematuria (93%) causing an anemia in 16 cases. The two mean histological forms were epidermoid carcinoma (37%) and adenocarcinoma (22%). 26% of patients were found to have extended invasive tumors (T4) at diagnosis. Metastatic disease was confirmed in 8 cases. Our patients were managed by a wide range of therapeutic modalities as total cystectomy with bilateral lymph node dissection (63%), palliative chemotherapy (30%), or concomitant radiochemotherapy (7%). 55.6% of patients were alive one year after diagnosis. Epidermoid carcinoma has the best prognosis followed by leiomyosarcoma and sarcomatoid carcinoma. Neuroendocrine carcinoma has the worst outcome. The overall 5-year survival rate is 33.3%.
CONCLUSION
CONCLUSIONS
The rarity and small size of these tumors justify the absence of clear and consensual therapeutic management. No role of total cystectomy concerning the conclusions could be drawn but elements suggest this may be the treatment of choice. The highly aggressive nature of those lesions justifies an aggressive and fast therapy when feasible which gives the best outcomes.
Identifiants
pubmed: 33082782
doi: 10.1155/2020/7563703
pmc: PMC7563043
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7563703Informations de copyright
Copyright © 2020 Youssef Kadouri et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Cancer. 1991 Apr 15;67(8):2165-72
pubmed: 1706216
J Urol. 1974 Dec;112(6):752-8
pubmed: 4140242
Bull Cancer. 2010;97 Suppl Cancer de la vessie:51-7
pubmed: 20534390
Hum Pathol. 2007 Jul;38(7):963-977
pubmed: 17574946
Ann Oncol. 2014 Sep;25 Suppl 3:iii102-12
pubmed: 25210080
J Urol. 1998 May;159(5):1497-503
pubmed: 9554341
Cancer Epidemiol. 2013 Apr;37(2):99-114
pubmed: 23200731
Prog Urol. 2002 Nov;12(5):1121-7
pubmed: 12536935
J Urol. 1984 Feb;131(2):262-3
pubmed: 6699954
Urology. 1985 Sep;26(3):252-5
pubmed: 3929441
Ugeskr Laeger. 1999 Nov 8;161(45):6203-4
pubmed: 10603757
Prog Urol. 1999 Feb;9(1):129-32
pubmed: 10212965
BJU Int. 2005 Mar;95(4):497-502
pubmed: 15705067
Urology. 1989 Apr;33(4):311-2
pubmed: 2929064
Ann Urol (Paris). 2000 Feb;34(1):20-7
pubmed: 10763420
Br J Urol. 1971 Feb;43(1):4-15
pubmed: 4926456
J Urol. 1990 Jan;143(1):119-21
pubmed: 2294239
Eur Urol. 2003 Dec;44(6):672-81
pubmed: 14644119
Ann Urol (Paris). 2003 Apr;37(2):75-8
pubmed: 12741197
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
J Urol. 1987 Dec;138(6):1390-2
pubmed: 3682066
Br J Urol. 1982 Oct;54(5):522-6
pubmed: 7171960
Cancer. 1998 Apr 15;82(8):1535-49
pubmed: 9554532